<DOC>
	<DOCNO>NCT01626378</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy TRx0237 treatment patient behavioral variant frontotemporal dementia ( bvFTD ) .</brief_summary>
	<brief_title>Safety Efficacy Study Evaluating TRx0237 Subjects With Behavioral Variant Frontotemporal Dementia ( bvFTD )</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<criteria>Diagnosis probable bvFTD Centrally rat frontotemporal atrophy score 2 great brain MRI MMSE ≥20 Age &lt; 80 year Modified Hachinski ischemic score ≤ 4 Females , childbearing potential , must practice true abstinence competent use adequate contraception agree maintain throughout study Subject , and/or , case reduce decisionmaking capacity , legally acceptable representative ( ) consistent national law is/are able read , understand , provide write informed consent Has one ( ) identify adult caregiver willing provide write informed consent his/her participation ; able read , understand , speak designate language study site ; either live subject see subject ≥2 hours/day ≥3 days/week ; agree accompany subject study visit ; able verify daily compliance study drug If currently take acetylcholinesterase inhibitor and/or memantine , subject must take medication ( ) ≥3 month . The dosage regimen must remain stable ≥6 week must plan remain stable throughout participation study . Able comply study procedure Significant central nervous system ( CNS ) disorder bvFTD Significant intracranial pathology see brain MRI scan Biomarker evidence underlie Alzheimer 's disease pathology Expressive language deficit Meets research criterion Amyotrophic Lateral Sclerosis motor neuron disease Meets diagnostic criterion probable bvFTD proven mutation produce nontau , nonTDP43 pathology Clinical evidence history stroke , transient ischemic attack , significant head injury unexplained recurrent loss consciousness ≥15 minute Epilepsy Rapid eye movement sleep behavior disorder Major depressive disorder , schizophrenia , psychotic disorder , bipolar disorder , substance ( include alcohol ) relate disorder Metal implant head ( except dental ) , pacemaker , cochlear implant , nonremovable item contraindication MRI Resides hospital moderate high dependency continuous care facility History swallow difficulty Pregnant breastfeed Glucose6phosphate dehydrogenase deficiency History significant hematological abnormality current acute chronic clinically significant abnormality Abnormal serum chemistry laboratory value Screening deem clinically relevant investigator Clinically significant cardiovascular disease abnormal assessment Preexisting current sign symptom respiratory failure Concurrent acute chronic clinically significant immunologic , hepatic , endocrine disease ( adequately treat ) and/or unstable major disease bvFTD Diagnosis cancer within past 2 year prior Baseline ( basal cell squamous cell skin cancer Stage 1 prostate cancer ) unless treatment result complete freedom disease least 2 year Prior intolerance hypersensitivity methylthioniniumcontaining drug , similar organic dye , excipients Treatment currently within 90 day Baseline follow medication ( unless otherwise note ) : Tacrine Amphetamine dexamphetamine Clozapine , olanzapine ( intent initiate therapy course study ) Carbamazepine , primidone Drugs warn precaution label methemoglobinemia approve dos Current prior participation clinical trial follow : Clinical trial product cognition within 3 month Screening ( unless confirm randomized placebo ) A clinical trial drug , biologic , device , medical food last dose/administration receive within 28 day prior Baseline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Behavioral Variant Frontotemporal Dementia</keyword>
	<keyword>bvFTD</keyword>
	<keyword>Frontotemporal Dementia</keyword>
</DOC>